VectorY

About:

VectorY is an integrated gene therapy company focused on development of therapeutics for CNS, somatic disorders and muscle diseases.

Website: https://www.vectorytx.com/

Top Investors: Benhamou Global Ventures, MRL Ventures Fund, Insight Partners, EQT Life Sciences, Eli Lilly & Company Foundation

Description:

VectorY is a fully integrated gene therapy company specializing in the development of novel therapeutics such as vectorized antibodies for both CNS and somatic disorders, with a particular emphasis on muscle diseases. It combines the therapeutic potential of antibodies and gene therapy to create long-term therapeutic solutions for large disease areas with significant unmet medical need. VectorY was founded in the Amsterdam Science Park in August 2020.

Total Funding Amount:

160M EUR

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Amsterdam, Noord-Holland, The Netherlands

Founded Date:

2020-01-01

Founders:

Anthony Newcombe, Barbara Sanders, Pavlina Konstantinova, Sander van Deventer

Number of Employees:

51-100

Last Funding Date:

2023-11-13

IPO Status:

Private

Industries:

© 2025 bioDAO.ai